TenPoint Therapeutics develops regenerative therapies for eye diseases. Its main approach is engineered cell-based therapeutics and in vivo reprogramming to replace damaged retinal or ocular tissue and potentially restore vision with a single, long-lasting treatment. Unlike many groups that work on generic regenerative methods, TenPoint focuses on the eye’s unique environment to direct therapies and reverse disease progression. The company aims to bring these regenerative solutions to patients by partnering with healthcare providers, with the ultimate goal of restoring sight and improving quality of life. The founding team comes from leading ocular research centers, giving them deep expertise in regenerative biology and translational medicine.
Company Size
51-200
Company Stage
Debt Financing
Total Funding
$305M
Headquarters
London, United Kingdom
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?